Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday increase of nearly 10%, currently up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] Group 1: Company Developments - Chuangsheng Group announced that its partner Inhibrx Biosciences, Inc. (INBX.US) reported positive primary results from the registration clinical study of the DR5 agonistic antibody ozekibart [1] - The study evaluated the efficacy of ozekibart as a monotherapy compared to a placebo in patients with advanced or metastatic, unresectable chondrosarcoma [1] - Based on these results, Inhibrx plans to submit a marketing application for the chondrosarcoma indication to U.S. regulatory authorities by the end of June 2026 [1] Group 2: Market Position - Chuangsheng Group holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1]
创胜集团-B现涨超4% ozekibart明年中前将提交美国适应症上市许可申请